Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | LS411N is a human colorectal adenocarcinoma cell line established by L. Suardet in 1985 at the Swiss Institute for Experimental Cancer Research. The cell line was derived from a primary cecal tumor resected from a 32-year-old Caucasian male patient, who was diagnosed with a poorly differentiated, Dukes stage B cecal adenocarcinoma. The cells exhibit a typical epithelial morphology and grow as an adherent monolayer. Molecular characterization of LS411N reveals a homozygous BRAF p.V600E mutation, biallelic loss of TP53 and PTEN, and a truncating mutation in the APC gene, while the KRAS and PIK3CA genes remain wild-type. The cell line displays high microsatellite instability (MSI-H)—a relatively rare feature in BRAF-mutated colorectal tumors—making it an ideal model for studying mismatch repair-deficient (dMMR), BRAF-driven disease. LS411N is tumorigenic in immunodeficient mice and possesses a near-triploid karyotype, with a modal chromosome number of approximately 73–75. This cell line is widely used in research concerning the efficacy of BRAF and MEK inhibitors, the mechanisms of resistance to EGFR-pathway-targeted therapies, and the preclinical evaluation of combination treatment regimens for MSI-H colorectal cancer. |
| Tissue | Cecum (primary tumor, in situ) |
| Disease | Cecal Adenocarcinoma; Colorectal Cancer (Dukes' type B, poorly differentiated) |
| Morphology | Epithelial |
| Gender | Male |
| Age | 32 years |
| Ethnicity | Caucasian |
| Product Format | Frozen |
| Growth Mode | Adherent |
| Biosafety Level | 1 (Biosafety classification is based on U.S. Public Health Service Guidelines) |
| Applications | 1. BRAF V600E colorectal cancer biology and BRAF/MEK/EGFR inhibitor efficacy studies 2. Investigation of acquired resistance to BRAF and MEK inhibition in MSI-H disease 3. Microsatellite-instability and mismatch-repair (MMR) pathway research 4. Combination-regimen screening for chemotherapeutics and targeted agents in CRC 5. TGF-β1/β2 signaling pathway research (LS411N serves as a non-responsive control) 6. Development of subcutaneous xenograft models in immunodeficient mice |
| Shipped In | Dry ice |
| Storage Temperature | −196°C |
| Characteristics | |
| Doubling Time | Approximately 24 hours |
| Tumorigenic | Yes, forms adenocarcinomas in nude mice following subcutaneous inoculation |
| Karyotype | Near-triploid; modal chromosome number 73–75 (range 70–76) with extensive rearrangements |
| Mycoplasma Test | Negative |
| Culture Conditions and Handling | |
| Subculturing | 1. Remove and discard the culture medium. 2. Briefly rinse the cell monolayer with PBS (Ca²⁺/Mg²⁺-free) to thoroughly remove residual serum. 3. Add 2.0 to 3.0 mL of 0.25% Trypsin–0.53 mM EDTA solution, and observe under an inverted microscope until the cell monolayer has dispersed (typically takes 2 to 5 minutes). 4. Add 6.0 to 8.0 mL of complete growth medium, and gently pipette to prepare a single-cell suspension. 5. Aliquot the cell suspension into new culture vessels. |
| Medium Renewal | 2 to 3 times per week |
| Subcultivation Ratio | A split ratio of 1:3 is recommended. |
| Culture Conditions | Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C |
| Cryopreservation | Complete growth medium supplemented with 5% (v/v) DMSO |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RO0176 | Cas9 Stable Cell Line - LS411N | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.